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Blood coagulation is thought to be initiated by plasma protease factor VIIa in complex with 
the membrane protein tissue factor. In contrast, coagulation factor XII (FXII)–mediated 
fibrin formation is not believed to play an important role for coagulation in vivo. We used 
FXII-deficient mice to study the contributions of FXII to thrombus formation in vivo. 
Intravital fluorescence microscopy and blood flow measurements in three distinct arterial 
beds revealed a severe defect in the formation and stabilization of platelet-rich occlusive 
thrombi. Although FXII-deficient mice do not experience spontaneous or excessive
injury-related bleeding, they are protected against collagen- and epinephrine-induced 
thromboembolism. Infusion of human FXII into FXII-null mice restored injury-induced 
thrombus formation. These unexpected findings change the long-standing concept that the 
FXII-induced intrinsic coagulation pathway is not important for clotting in vivo. The results 
establish FXII as essential for thrombus formation, and identify FXII as a novel target for 
antithrombotic therapy.
 
Injury to a blood vessel triggers activation of
blood platelets and the plasma coagulation sys-
tem, leading to formation of a blood clot con-
taining platelets and fibrin. Although clot for-
mation is critical for limiting posttraumatic
blood loss, this process may also occlude diseased
vessels leading to diseases such as myocardial
infarction and stroke that are still leading
causes of death in industrialized nations. In the
waterfall or cascade models of fibrin clot for-
mation, proposed in 1964 by Macfarlane and
by Davie and Ratnoff, respectively (1, 2), plasma
coagulation proceeds through a series of se-
quential activations of plasma serine proteases
culminating in the generation of thrombin,
which converts plasma fibrinogen to fibrin.
Thrombin also activates platelets, and activated
platelets, in turn, facilitate thrombin generation
by exposing procoagulant phosphatidylserine
(PS) on the outer surface of their membranes
(for review see reference 3).
The original cascade/waterfall models de-
scribed two distinct pathways for initiating coag-
ulation, triggered by either vessel wall (extrinsic)
or bloodborne (intrinsic) factors, that converge
on a common pathway leading to thrombin
generation and fibrin formation. Initiation of
coagulation through the extrinsic pathway occurs
when the plasma protease factor VIIa comes
into contact with the integral membrane protein
tissue factor (TF), which is present in suben-
dothelial layers of the vessel but not on the
vessel’s luminal surface. TF on circulating mi-
crovesicles may also contribute to coagulation
by sustaining thrombin generation on the surface
of activated platelets (for review see reference 4).
The intrinsic pathway of coagulation is initiated
when coagulation factor XII (FXII), also referred
to as Hageman factor, comes into contact with
negatively charged surfaces in a reaction (contact
activation) involving the plasma proteins high
molecular mass kininogen and plasma kallikrein.
Although FXII is activated by a variety of poly-
anions, including constituents of subendothelial
matrix (glycosaminoglycans and collagens),
sulfatides, nucleosomes, and nonphysiological
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materials (glass, ellagic acid, kaolin, and cilica; references
5 and 6) the mechanisms responsible for FXII activation
in vivo are unknown. Induction of fibrin clot formation
through contact activation–mediated activation of FXII is
the basis of the activated partial thromboplastin time (aPTT)
assay, a commonly used method for the global assessment of
plasma coagulation in clinical settings.
Despite its obvious importance to blood coagulation in
vitro, the pathophysiologic significance of the FXII-trig-
gered intrinsic pathway of coagulation has been questioned
for 
 
 
 
50 yr, based on the important clinical observation that
hereditary deficiency of FXII is not associated with abnormal
bleeding. The absence of a bleeding phenotype in FXII defi-
ciency, in contrast to deficiencies of components of the ex-
trinsic cascade such as factor VII and TF (7, 8), has led to the
reasonable hypothesis that fibrin formation in vivo is initi-
ated largely, if not exclusively, through factor VIIa–TF (4,
9). The factor VIIa–TF–initiated model for hemostasis is
supported by the observations that factor VIIa–TF can acti-
vate factor IX (10), and that factor XI, a major substrate for
activated FXII (FXIIa) during contact-initiated clotting, can
be activated by thrombin independently of FXII (11).
We used FXII-deficient mice to assess the in vivo signif-
icance of the intrinsic pathway of coagulation in thrombus
formation. In agreement with observations in FXII-deficient
humans, these mice have normal bleeding times and show
no spontaneous bleeding. However, in vivo fluorescence
microscopy revealed that even though the initial adhesion of
platelets at sites of injury is not affected by FXII deficiency,
the subsequent formation and stabilization of three-dimen-
sional thrombi is severely impaired. This defect is observed
in several locations in the vascular system in response to dif-
ferent types of injury and is completely reversed by the infu-
sion of human FXII. These findings demonstrate that FXII-
enhanced thrombin generation, or another unidentified
FXII-dependent process, is required for arterial thrombus
formation in vivo.
 
RESULTS
Factor XII is essential for contact activation, but not for 
controlling bleeding after injury
 
We have previously reported the development of an FXII-
deficient mouse line (12). Mice homozygous for the FXII
null allele (FXII
 
 
 
/
 
 
 
) are healthy, fertile, and phenotypically
indistinguishable from their wild-type littermates. Similar to
humans, FXII
 
 
 
/
 
 
 
 mice do not suffer from spontaneous hem-
orrhage or pathological vascular thrombosis. Consistent with
our initial characterization of these animals, we found that
FXII
 
 
 
/
 
 
 
 mice do not have prolonged bleeding compared
with wild-type mice in a tail bleeding time assay (369.5 
 
 
 
201.7 s and 355.9 
 
 
 
 176.1 s, respectively; Fig. 1 A). Addi-
tionally, a detailed histological analysis did not reveal any
correlation of abnormal bleeding or thrombosis in various
tissues such as the lung, kidney, liver, small bowel, heart,
brain, and spleen (unpublished data). Similarly, as described
for humans lacking FXII (13), FXII
 
 
 
/
 
 
 
 mice did not suffer
from inadequate bleeding during the various surgical chal-
lenges performed in the study despite having prolonged
plasma aPTT (71 
 
 
 
 18 s) and recalcification times (412 
 
 
 
 78 s;
wild-type values are 25 
 
 
 
 4 s and 210 
 
 
 
 31 s, respectively;
Fig. 1 B). Furthermore, as is the case with FXII-deficient hu-
mans, the prothrombin time of FXII
 
 
 
/
 
 
 
 mouse plasma,
which evaluates TF-initiated coagulation, is similar to wild-
type plasma collected by retroorbital puncture (8.9 
 
 
 
 1.3 s
and 9.1 
 
 
 
 1.3 s, respectively; Fig. 1 B). Peripheral blood cell
counts in FXII
 
 
 
/
 
 
 
 and wild-type mice did not differ. The
addition of normal human plasma to FXII-deficient murine
plasma, and vice versa, corrected the defects in aPTT assays,
indicating that human and murine FXII function similarly (in
50% mixtures the aPTT was 130% of wild type, and 
 
 
 
90%
FXII-containing plasma completely restored the aPTT pro-
longation found in FXII-deficient species). Using an aPTT
assay based on human FXII-deficient plasma, it was deter-
mined that FXII
 
 
 
/
 
 
 
 mice have 
 
 
 
1% of the FXII level of
wild-type mice. Western blots of plasma confirmed the ab-
sence of FXII in the plasma of FXII
 
 
 
/
 
 
 
 mice, whereas levels
of the contact factors high molecular mass kininogen and
prekallikrein were normal (Fig. 1 C). To test the contribu-
tion of FXII to clotting in vitro, we determined the recalcifi-
cation time in the presence of resting platelets or platelets
stimulated with the calcium ionophore A23187, a very po-
tent stimulus of PS exposure and microparticle formation,
before induction of clot formation. In wild-type blood, the
addition of A23187-stimulated platelets decreased the clot-
ting time 
 
 
 
2.5-fold compared with resting platelets. This ef-
fect was not detectable in FXII-deficient blood, suggesting
that activated platelets may promote clot formation in a
FXII-dependent manner (Fig. 1 D). Similar results were ob-
served in human FXII-deficient plasma (not depicted).
Platelets interact with and contribute to the activation of
several coagulation factors and the central coagulation prod-
uct thrombin is a potent platelet activator (for review see ref-
erences 14, 15). To discriminate between platelet and FXII-
induced effects on thrombus formation, we induced clotting
using either kaolin, which classically activates FXII but has
no direct effect on platelets, or collagen, which activates
both FXII and platelets. In the presence, but not in the ab-
sence, of platelets, collagen was superior to kaolin for clot
formation in wild-type plasma (Fig. 1 E). In contrast, in
platelet-rich plasma (PRP) derived from mice deficient in
the FcR 
 
 
 
 chain, which also lack the activating collagen re-
ceptor GPVI (16) in their platelets and, thus, cannot be acti-
vated by collagen, the relative potency of kaolin and col-
lagen was similar to platelet-free plasma (PFP). On the other
hand, in plasma lacking FXII, in vitro clot formation in re-
sponse to either agonist was severely defective in the pres-
ence or absence of platelets. Further experiments confirmed
that the clotting defect in FXII-deficient plasma in response
to collagen was based on impaired thrombin formation (Fig.
1 F). In summary, these results demonstrated that activated/ 
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procoagulant platelets promote FXII-induced thrombin and
clot formation. It will be the subject of further studies to dis-
tinguish whether FXII may be directly activated by procoag-
ulant platelets and/or whether activated platelets are merely
recruited downstream of FXII into the growing thrombus.
Furthermore, the results demonstrate that FXII
 
 
 
/
 
 
 
 mice and
FXII-deficient humans have similar plasma coagulation pro-
files and therefore established the FXII
 
 
 
/
 
 
 
 animals as an ap-
propriate model to study the impact of FXII on clot forma-
tion in vivo.
 
FXII contributes to collagen-induced thromboembolism 
in vivo
 
To determine the consequences of FXII deficiency in vivo,
we first tested wild-type and FXII
 
 
 
/
 
 
 
 mice in a model of le-
thal pulmonary thromboembolism induced by infusion of a
mixture of collagen and epinephrine. All wild-type mice (19
out of 19) died within 5 min, with 
 
 
 
95% reduction in cir-
culating platelet counts within 2 min of challenge (Fig. 2, A
and B). Consistent with a previous report (17), FcR 
 
 
 
chain–deficient mice are protected from death in this model
and experience only moderate reductions in platelet count. 5
out of 14 FXII
 
 
 
/
 
 
 
 mice (37.5%) survived this challenge, al-
though their peripheral platelet counts were reduced to a
similar degree as in the wild-type controls. This suggests that
the protection conferred by FXII deficiency is not caused by
a platelet activation defect, but rather a defect in thrombin
generation or some other FXII-related activity. Consistent
with this premise, in vitro studies demonstrated that platelet
aggregation in response to collagen and ADP is normal in
PRP from FXII
 
 
 
/
 
 
 
 mice (Fig. 2 C). Histologic sections of
lung tissue and analysis of thrombi in the lungs are shown in
Fig. 2 D. Although the majority of vessels are obstructed in
wild-type mice, there is a clear reduction in the number of
occluded vessels in FXII
 
 
 
/
 
 
 
 mice (survivors and nonsurvi-
vors). In agreement with previous observations, virtually no
thrombi were found in the lungs from FcR
 
 
 
 
 
/
 
 
 
 mice.
These results suggest that collagen triggers both platelet and
Figure 1. Hemostasis and coagulation in FXII deficient mice. (A) Tail 
bleeding times for wild-type (n   12) and FXII /  (n   11) mice. Each 
symbol represents one individual. (B) Peripheral blood counts in thousands/
microliter and coagulation parameters for FXII /  and wild-type mice. 
Values are mean   SD for 10 mice of each genotype. WBC, white blood 
cells; aPTT, activated partial thromboplastin time; PT, prothrombin time. 
(C) Western blots of wild-type or FXII deficient plasma (0.3  l per lane) 
using primary antibodies recognizing the contact proteins FXII ( FXII), 
plasma kallikrein ( PK), and high molecular mass kininogen ( HK). The 
arrowheads point to FXII (left), plasma kallikrein (middle), and high molecular 
mass kininogen (right). Numbers indicate molecular mass standards. 
(D) Wild-type PFP or FXII-deficient plasma was reconstituted with platelets 
stimulated with calcium ionophore A23187 ( ) or buffer ( ), and recalci-
fication clotting times were determined. Reduction of the clotting time is 
given relative to PFP substituted with buffer (n   6). (E) Recalcification 
clotting times were determined in PRP (left) and PFP (right) from wild-
type (129Sv and C57BL/6), FXII / , and FcR  /  mice after activation with 
kaolin (black bars) or collagen (white bars). Mean   SD from six experi-
ments is given. (F) Thrombin generation in PRP (white bars) and PFP (black 
bars) from wild-type and FXII /  mice initiated by the addition of 30  g/ml 
of collagen. Thrombin formation was analyzed using the chomogenic 
substrate S-2238, and absorbance was detected at a 405-nm wavelength 
after incubation for 20 min. Data shown are mean   SD (n   6). 
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FXII activation, which synergize in this model to form oc-
clusive pulmonary thrombi.
 
Defective arterial thrombus formation in FXII
 
 
 
/
 
 
 
 mice
 
Pathological thrombus formation in arteries is thought to be
initiated by fissuring or other disruption of an atherosclerotic
plaque, leading to local activation of platelets and plasma co-
agulation on exposed subendothelial layers of the vessel. We
studied the effect of FXII deficiency on thrombus formation
in wild-type and FXII
 
 
 
/
 
 
 
 mice using three models of arterial
injury. In the first model, oxidative injury was induced in
mesenteric arterioles, and thrombus formation was examined
by in vivo fluorescence microscopy. Wild-type and FXII
 
 
 
/
 
 
 
mice received 10
 
8 
 
fluorescently labeled platelets from donors
of the same genotype, and injury was induced by topical ap-
plication of filter paper saturated with 20% ferric chloride
(FeCl
 
3
 
). FeCl
 
3
 
 induces formation of free radicals, leading to
disruption of the vascular endothelium. Platelets rapidly in-
teracted with the injured vessel wall, and 5 min after in-
jury the number of firmly adherent platelets was similar in
FXII and wild-type mice (Fig. 3 A). In wild-type mice, ad-
ditional platelets were recruited into the growing thrombus.
Thrombi 
 
 
 
20 
 
 
 
m developed in 100% of wild-type vessels
tested (17 out of 17) within 10 min of injury (Fig. 3 B), ulti-
mately leading to complete occlusion in 94.1% (16 out of
17) of vessels within the 40-min observation period (mean
occlusion time: 25.6 
 
 
 
 8.9 min; Fig. 3 C). In contrast, for-
mation of microaggregates or thrombi did not occur in 50%
(7 out of 14) of vessels in FXII
 
 
 
/
 
 
 
 mice (Fig. 3 B). In the re-
maining vessels (7 out of 14), thrombi formed that were un-
stable and detached from the vessel wall (Fig. 3 D). In no
FXII
 
 
 
/
 
 
 
 vessel did a thrombus 
 
 
 
20 
 
 
 
m in diameter remain
attached to the injury site for 
 
 
 
1 min. Consequently, no
vessel occluded within the 40-min observation period in
FXII
 
 
 
/
 
 
 
 mice (Fig. 3 C). To assess the contribution of FXII
to thrombus formation more quantitatively, we tested mice
heterozygous for the FXII null allele (FXII
 
 
 
/
 
 
 
) that have
half of the FXII plasma antigen and activity levels of wild-
type mice and a normal aPTT (26 
 
 
 
 5 s vs. 25 
 
 
 
 5 s for
FXII
 
 
 
/
 
 
 
 and wild-type mice, respectively; reference 12).
Platelet adhesion occurred normally in FXII
 
 
 
/
 
 
 
 animals, and
thrombi 
 
 
 
20 
 
 
 
m developed in 100% of the vessels (14 out
of 14) within 10 min of injury, leading to complete occlu-
sion in 11 out of 14 vessels (mean occlusion time: 29.5 
 
 
 
7.7 min). In the other three arterioles, stable thrombi oc-
cluded 
 
 
 
90% of the vessel lumen but did not reach com-
plete occlusion. Collectively, these results demonstrate that
FXII is required for the propagation and stabilization of
platelet-rich thrombi in FeCl
 
3
 
-injured arterioles and suggest
that FXII-mediated activation of coagulation is involved in
this model. To examine this possibility further, we tested
factor XI–deficient mice in the same model. Factor XI is the
principal substrate of FXIIa in the intrinsic pathway of the
coagulation cascade in vitro, and a similar defect in thrombus
formation would be expected in FXII- and factor XI–defi-
cient mice if this pathway is operating in vivo. Similar to
FXII
 
 
 
/
 
 
 
 mice, normal platelet adhesion at the site of injury
was detectable during the first 5 min after injury in factor
XI–deficient mice (Fig. 3 A), with formation of thrombi in
only four out of nine (44.4%) vessels studied. In the remain-
Figure 2. Collagen-induced pulmonary embolism model. (A) Mortality 
associated with i.v. injection of 0.8 mg/kg of collagen and 60  g/kg of epi-
nephrine. All wild-type mice died within 5 min. Animals alive 30 min after 
challenge were considered survivors. (B) Platelet counts in control (n   19), 
FXII /  (n   14), and FcR  /  (n   5) mice 2 min after infusion of collagen/
epinephrine. (C) Heparinized PRP from wild-type and FXII /  mice was 
stimulated with 10  g/ml of collagen or 5  M ADP, and light transmission 
was recorded in a standard aggregometer. Representative results for each 
genotype are shown (n   6). (D) Hematoxylin and eosin–stained sections 
from lungs of mice 2 min after collagen/epinephrine infusion. Thrombi 
per visual field were counted at 20 . Mean   SD for 100 fields is shown. 
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ing vessels, microaggregates and thrombi were unstable and
broke loose from the site of injury (Fig. 3 D). No vessel oc-
cluded in factor XI–deficient animals during the observation
period. These data confirm and extend the previous observa-
tion that FXI-deficient mice are protected from vascular oc-
clusion in a FeCl3 carotid artery injury model (18).
FeCl3-induced arterial thrombus formation is dependent
on platelet activation and thrombin generation, but it is un-
clear how well this type of injury mimics naturally occurring
arterial thrombus formation at the site of rupture of an ath-
erosclerotic plaque. As it is possible that FeCl3-induced oxi-
dative damage produces conditions that artifactually favor
FXII-dependent processes, the effect of FXII deficiency was
assessed in a second well-established arterial thrombosis
model in which injury is induced mechanically in the aorta,
and blood flow is monitored with an ultrasonic flow probe.
After a transient increase directly after injury, blood flow pro-
gressively decreased for several minutes in all animals. In all
wild-type mice (10 out of 10), this decrease resulted in com-
plete and irreversible occlusion of the vessel within 1.6–11.1
min after injury (mean occlusion time: 5.3   3.0 min; Fig. 4
A). Although a progressive reduction in blood flow was ob-
served during the first several minutes after injury in FXII / 
mice, occlusion occurred in only 4 out of 10 mice. Occlusive
thrombi were all unstable and rapidly embolized so that
blood flow was reestablished within 10–115 s after occlusion.
No vessel in which flow was reestablished occluded a second
time, and all FXII /  mice displayed essentially normal flow
rates through the injured vessel at the end of the 40-min ob-
servation period. Similar results were obtained with factor
XI–deficient mice, where 9 out of 11 vessels were not oc-
cluded at the end of the observation period (Fig. 4 A).
The defect in arterial thrombus formation in FXII / 
mice was confirmed in a third model in which platelet re-
cruitment into thrombi in the injured carotid artery is studied
by in vivo fluorescence microscopy. Platelets purified from
donor mice of the appropriate genotype were fluorescently
labeled and injected into recipient mice. Vascular injury was
induced by ligation of the carotid artery, a process that con-
sistently causes disruption of the endothelial layer and fre-
quent breaching of the internal elastic lamina, followed by
rapid collagen-dependent platelet adhesion and thrombus
formation at the site of injury (19). Large stable thrombi that
did not embolize formed rapidly in wild-type animals within
5 min (thrombus area: 102.821   39.344  m2). In contrast,
only small- and medium-sized aggregates formed in FXII / 
mice, which frequently detached from the site of injury (Fig.
4, B and C). Consequently, the thrombus area was dramati-
Figure 3. Defective thrombus formation in FeCl3-injured mesenteric 
vessels in FXII /  and factor XI /  mice. Thrombus formation in vivo 
was monitored on mesenteric arterioles after topical application of 20% 
FeCl3. (A) Mean   SD of platelets adherent at 5 min (129Sv wild type, 
n   14; FXII / , n   14; FXII / , n   11; FXI / , n   9). (B) The number of 
vessels in which one or more thrombi  20  m in diameter formed during 
the 40-min observation period. (C) Time to complete occlusion after injury. 
Each symbol represents one monitored arteriole. (D) Representative 
images of one experiment.
Figure 4. Defective thrombus formation in the injured aorta and 
carotid artery in FXII /  and factor XI /  mice. (A) Thrombosis was 
induced in the aorta of wild-type (n   10), FXII /  (n   10), and FXI /  
(n   11) mice by one firm compression with a forceps. Blood flow was 
monitored with a perivascular ultrasonic flow probe until complete occlusion. 
The experiment was stopped after 40 min. Each symbol represents one 
individual. (B) Mechanical injury to the carotid artery was induced by 
ligation with a surgical filament. 5 min after removal of the filament, 
thrombus areas ( m2) in wild-type and FXII /  (n   10) mice were mea-
sured and are expressed as mean   SD. (C) The photomicrographs show 
representative images 5 min after injury.COAGULATION FACTOR XII AND THROMBOSIS | Renné et al. 276
cally reduced in FXII /  mice 5 min after injury (8.120  
13.900  m2), whereas primary platelet adhesion on the vessel
wall appeared not to be defective.
Exogenous human FXII restores arterial thrombus formation 
in FXII /  mice
To determine whether the severe defect in thrombus forma-
tion in FXII /  mice results from the absence of plasma
FXII or a secondary effect of chronic FXII deficiency that
indirectly alters sensitivity to prothrombotic stimuli, we
studied arterial thrombus formation in FXII /  mice after
intravenous administration of human FXII (2  g/g body
weight). This treatment corrected the prolonged aPTT clot-
ting time of FXII-deficient murine plasma to normal (27  
6 s) and completely restored arterial thrombus formation.
In all FeCl3-injured mesenteric arterioles in wild-type or
FXII /  mice treated with human FXII, thrombi  20  m
formed within 10 min after injury, and all vessels were oc-
cluded within the observation period (Fig. 5, A and B) with
the exception of a single vessel in a wild-type animal. In fact,
there was a slight tendency toward faster occlusion in the re-
constituted FXII /  mice compared with untreated wild-
type control mice (mean occlusion time: 22.7   8.2 min vs.
25.6   8.9 min). A similar result was obtained with mechan-
ical injury of the aorta (Fig. 5 C), with all vessels completely
occluded within 10 min of injury. These results confirmed
that the absence of plasma FXII protects FXII /  mice from
arterial thrombus formation in these models.
DISCUSSION
Although the importance of FXII for contact activation–ini-
tiated coagulation has been recognized for  50 yr (20), the
protein is not considered to be an important component of
the hemostatic mechanism, as humans lacking FXII do not
have a bleeding diathesis. Indeed, for many years FXII has
been suspected of having antithrombotic (profibrinolytic),
rather than prothrombotic properties, based on reports indi-
cating an association between FXII deficiency and venous
thrombosis (21, 22) and myocardial infarction (23). How-
ever, this premise has been challenged recently by Girolami
et al., who demonstrated that in most cases of thrombosis as-
sociated with FXII deficiency, other congenital or acquired
prothrombotic risk factors are present (24). Indeed, large
clinical studies have not identified a correlation between
FXII deficiency and bleeding or thrombosis (25, 26). Cur-
rent models of hemostasis stress the importance of the factor
VIIa–TF complex in the initiation of thrombin formation.
The importance of this pathway is highlighted by the fact
that mice lacking factor VII or TF die perinatally in utero
from apparent severe hemorrhage (7, 8). Although it is clear
that the TF exposed at a site of vessel injury is well posi-
tioned to initiate thrombin generation, it has puzzled investi-
gators as to how thrombin generation proceeds on the sur-
face of a growing thrombus once the factor VIIa–TF at the
wound site is covered by the clot and/or neutralized by in-
hibitors such as TF pathway inhibitor (27, 28). There is evi-
dence that TF is expressed on procoagulant microparticles
that are released at sites of injury or that circulate in blood.
These particles can be incorporated into a growing thrombus
in a P-selectin–dependent manner (29). Indeed, mice ex-
pressing low levels of TF display defective arterial thrombus
formation, although it is unclear whether this is related to a
lack of vessel wall or blood cell–derived TF (30, 31). How-
ever, the existence of active TF in blood is still a matter of
discussion (32), and other mechanisms contributing to fibrin
formation are possible.
We used three in vivo models to study platelet recruit-
ment and thrombus formation at sites of arterial injury in
FXII-deficient mice and observed a profound defect in the
formation and stabilization of platelet-rich thrombi. Similar
results were obtained in a pulmonary thromboembolism
model. Additionally, in the FeCl3 model, we consistently
observed severely reduced thrombus stability not only in
mesenteric arterioles but also in adjacent venules of FXII / 
mice, indicating that FXII may also be relevant to thrombus
formation in the venous circulation, although further studies
will be required to confirm this. Together, these results sug-
gest that a TF-independent pathway may be operating in the
Figure 5. Thrombus formation in FXII /  mice reconstituted with 
exogenous FXII. FXII-deficient animals received human FXII (hFXII, 2 mg/kg 
of body weight), and thrombus formation after FeCl3-induced injury was 
analyzed. (A) Time to complete occlusion after injury. Each symbol represents 
one monitored arteriole. (B) Representative images from one experiment. 
(C) FXII /  mice received 2 mg/kg hFXII, and aortic thrombosis was induced 
by compression with a forceps. Blood flow was monitored with a perivascular 
ultrasonic flow probe. Each symbol represents one individual.JEM VOL. 202, July 18, 2005 277
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propagation of pathologic thrombus formation in mice. The
protective effect of FXII deficiency in these models is re-
versed by infusions of human FXII, demonstrating that the
absence of plasma FXII is responsible for the observed phe-
notype (Fig. 5). These results appear to conflict with the rea-
sonable proposition that the coagulation proteins involved in
pathologic thrombus formation are the same as those that are
also important for normal hemostasis (cessation of bleeding
at a wound site). Our results support the interesting possibil-
ity that hemostasis and thrombosis may be facilitated by dif-
ferent, though probably largely overlapping, mechanisms.
Several recent reports support this premise. Mice lacking
plasma fibronectin or the secreted growth arrest-specific
gene 6 product (Gas6) do not have prolonged bleeding times
and do not spontaneously bleed. However, fibronectin-defi-
cient mice do not form occlusive arterial thrombi, and Gas6-
null mice are protected from thromboembolism (33, 34).
Similarly, mice lacking the platelet collagen binding GPVI–
FcR   chain complex have a profound defect in injury-induced
arterial thrombus formation, but only minor hemostatic
abnormalities (19).
We cannot exclude the possibility that there are species-
specific differences in the functions of FXII. This will be an
important issue to resolve, as the models used in our studies
are widely used for evaluating the importance of blood and
blood vessel constituents to thrombus formation, as well as
testing prospective antithrombotic agents. FXII-deficient
mice, like their human counterparts, have prolonged aPTTs
in the absence of a bleeding diathesis. Furthermore, plasma
mixing studies demonstrate that murine FXII functions nor-
mally in human plasma in vitro, whereas infusion of human
FXII into FXII /  mice results in a phenotype similar to
that of wild-type mice in thrombosis models. Clinical stud-
ies have associated elevated plasma FXIIa levels with an in-
creased prevalence of coronary heart disease and other
known plasma cardiovascular risk factors (35, 36), support-
ing the notion that an FXII-dependent pathway might con-
tribute to thrombosis in humans. It remains to be deter-
mined if FXII activation is the cause or the consequence of
the underlying vascular disease. A particular FXII single
nucleotide polymorphism (46C T) has been linked with
lower FXIIa and FXII plasma levels and protection from
coronary artery diseases in British patients (35). Because the
same single nucleotide polymorphism has been reported to
be a risk factor for ischemic stroke in the Spanish popula-
tion (37), environmental and/or other genetic factors may
influence the effects of FXII plasma levels on thrombotic
risk. Indeed, clinical studies have shown that elevated FXIIa
levels are associated with an increased risk for coronary
heart disease. However, in these patients, FXIIa activation is
linked with other risk factors such as elevated cholesterol,
triglycerides, or fibrinogen (38). Moreover, elevated FXIIa
levels have been reported as a prognostic risk factor for re-
current coronary events (39), supporting the premise that
FXII contributes to thrombus formation in humans. Simi-
larly, FXIIa has been shown to efficiently activate the coag-
ulation cascade in primates (40).
Data from heterozygous FXII /  mice show that FXII at
half the normal plasma level is sufficient for the formation of
large and stable arterial thrombi, though with a slightly re-
duced rate of complete vessel occlusion (Fig. 3). This sug-
gests that partial FXII deficiency may provide, at most, lim-
ited protection from stroke or myocardial infarction in
humans. In contrast, Girolami et al. followed 21 patients
with severe (homozygous) FXII deficiency with a mean ob-
servation period of 16 yr and did not observe a thrombotic
event (41). Clearly, larger clinical studies will be required to
define the significance of severe (homozygous) FXII defi-
ciency for a complex disease such as arterial thrombosis.
It seems very unlikely that resistance to thrombus forma-
tion in FXII-deficient mice is an artifact of the type of injury
inflicted on the vessel, or the vascular bed tested, as observa-
tions were consistent across several models and different vas-
cular beds. Furthermore, we have no evidence that FXII
functions differently in mice and humans. The mechanism
through which FXII is recruited into the thrombotic process
is not clear. Plaque rupture or fissuring results in the exposure
of collagen fibrils and other basement membrane components
to flowing blood, and it is likely that there is similar exposure
in our arterial injury models, which disrupt the vascular en-
dothelium. Early work demonstrated that collagen activates
FXII (for review see reference 5), although not all investiga-
tors came to this conclusion (42). An explanation for the dis-
crepancy may be that procoagulant activities of collagens are
highly dependent on the type, available surface area, charge,
and method of preparation of the collagen (43). We have ob-
served that fibrillar collagen type I, the major collagen in
blood vessels, activates FXII in plasma clotting assays (Fig. 1).
Collagen may not be the only pathophysiological activator of
FXII. Other candidates include substances liberated from dis-
integrating cells or exposed in the extracellular matrix (ECM)
such as HSP90 (44) or soluble and insoluble polyanions, such
as nucleosomes or glycosaminoglycans (45). Based on our re-
sults, we speculate that FXII-driven thrombin generation and
fibrin deposition might proceed directly on platelet surfaces.
This hypothesis is supported by two observations. First,
thrombin generation initiated by collagen is enhanced in the
presence of platelets (Fig. 1 E). Second, collagen, which acti-
vates platelets and FXII, is superior to kaolin in aPTT assays
in PRP but not PFP, and that this difference is not observed
in FXII-deficient plasma (Fig. 1 F).
Based on our results, we propose the model for patho-
logic arterial thrombus formation depicted in Fig. 6. At sites
of vascular injury, platelets come in contact with the exposed
subendothelial ECM. Platelets are initially tethered to the
ECM by von Willebrand factor through platelet glycopro-
tein Ib (46). Activation and adhesion then proceeds through
interactions between platelet collagen receptors such as
GPVI and integrin  2 1 and the ECM (47). Factor VIIa–TF
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lets into the growing thrombus. Although FXII and factor
XI may be activated during this early phase, these proteins
appear to have little effect on platelet adhesion or recruit-
ment. As the thrombus grows, the exposed ECM and TF are
covered, and TF is inactivated by TF pathway inhibitor re-
leased from activated platelets (28). Under these conditions,
additional mechanisms are required to maintain spatio-tem-
poral thrombin generation to activate newly recruited plate-
lets and consolidate fibrin formation in the growing throm-
bus. It is in this propagation phase that FXII /  and factor
XI–deficient mice appear to be defective. Therefore, we
propose that FXII activation and FXII-driven thrombin for-
mation might proceed on the surface of activated platelets
(Fig. 6 B). Indeed, it has been suggested that “platelets can
provide a surface, perhaps similar to that provided by such
negatively charged substances as kaolin or glass” (48), that fa-
cilitate FXII activation. Because procoagulant platelets ex-
pose PS on their surface (for review see reference 49) that fa-
cilitates several coagulation protease reactions, it is tempting
to speculate that this negatively charged surface might in-
duce a conformational change in FXII, resulting in activa-
tion. Such a reaction has been described for sulfonated gly-
colipid micells that efficiently activate FXII in plasma (50).
Therefore, the surface of activated platelets may at least
partly provide the long sought after “contact activation sur-
face.” This notion is supported by the observation that
A23187-activated PS-exposing platelets promote clot forma-
tion only in the presence of FXII (Fig. 1 D). It is quite possi-
ble that other structures exposed on or released from acti-
vated platelets mediate FXII activation. It will be important
to identify these structures and the mechanisms underlying
platelet-dependent FXII activation in detail. One approach
could be to use annexin V and/or inhibitory antibodies
against platelet surface molecules in clotting assays to inter-
fere with possible sites of FXII association. It will also be in-
teresting to directly visualize FXII recruitment into the
growing thrombus in vivo and to compare it with recruit-
ment of TF in order to better understand how these two
proteins coordinate thrombus formation.
In conjunction with the observation that mice expressing
low levels of TF display impaired arterial thrombus forma-
tion, our results suggest that factor VIIa–TF and FXII coop-
erate and synergize in an integrated manner in vivo and,
thus, are both required for formation of an occlusive throm-
bus. The absence of a bleeding diathesis in FXII /  mice in-
dicates that FXII is not required to seal a hole in a vessel wall
(hemostasis). However, FXII-mediated thrombin formation
occurs in vivo and is believed to contribute to thrombus
generation in sepsis-associated disseminated intravascular
coagulation (51). Therefore, FXII-driven thrombin and
thrombus generation may contribute to the control of bleed-
ing when blood comes in contact with glycosaminoglycans
(45) or cerebroside sulfates (50) that readily activate FXII.
Furthermore, bacteria assemble contact system proteins on
their surfaces and activate FXII (52). Therefore, FXII might
participate in the control of blood loss on sites of infections
and inflammatory responses. We are aware that this model
does not satisfactorily answer the long standing question re-
garding the physiologic role of FXII, but our findings raise
the interesting possibility that formation of a large thrombus
may serve nonhemostatic functions, such as inhibition of the
spread of invading pathogens or toxins within the blood
stream. FXII-deficient mice will be an important tool for
studying other contact system-linked diseases, such as in-
flammation and sepsis (52), complement activation (53, 54),
and kinin-mediated vascular leakage (55).
In summary, although FXII appears to be dispensable for
normal hemostasis, we have demonstrated a central role for
FXII in pathologic thrombus formation in vivo. These find-
ings establish FXII as a promising new target for antithrom-
botic therapies that might be associated with low or no risk
of excessive bleeding.
MATERIALS AND METHODS
Animals. All experiments and animal care were approved by the local An-
imal Care and Use Committee. Mice homozygous for null mutations in the
factor XI and FXII genes were generated as previously described (12, 56).
Mice deficient in the FcR   chain (57) were purchased from Taconics.
FXII /  mice were inbred for nine generations to the 129/SvJ background.
Factor XI /  and FcR  /  mice were inbred to C57BL/6J for more than
nine generations. Corresponding wild-type C57B/6J or 129/SvJ mice were
used as controls.
Platelet preparation and aggregometry. Murine platelets were pre-
pared according to established protocols (58). Platelet aggregation in 200  l
PRP (0.5   106 platelets/ L) stimulated with 10  g/ml collagen or 5  M
ADP was determined by changes in light transmission using a standard ag-
gregometer (Fibrintimer 4; APACT Laborgeräte und Analysensysteme).
Changes through 10 min were expressed as arbitrary units with 100% trans-
mission represented by platelet-poor plasma.
Tail bleeding time. Mice were anesthetized by i.p. injection of tribro-
moethanol (0.15 ml/10 g of body weight; Sigma-Aldrich), and the distal
Figure 6. A model of arterial thrombus formation. (A) Initiation of 
thrombus formation at sites of vascular lesions is predominantly caused 
by TF and collagens exposed in the subendothelial matrix. TF in complex 
with FVII initiates thrombin formation, which promotes fibrin formation 
and platelet activation. The contribution of FXII in this early phase of 
thrombus formation is minor. (B) FXII activity on the exposed surface of 
the thrombus contributes to thrombin generation and additional platelet 
activation, propagating thrombus growth. Accordingly, FXII, as well as 
factor XI, deficiency severely impairs thrombus formation.JEM VOL. 202, July 18, 2005 279
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3-mm segment of the tail was removed with a scalpel. Bleeding was moni-
tored by gently absorbing the bead of blood with a filter paper at 15-s inter-
vals without touching the wound. Bleeding was stopped manually if it con-
tinued for  20 min.
Preparation of platelets for intravital microscopy. Heparinized
blood was centrifuged at 250 g for 10 min, and PRP was gently transferred
to a fresh tube. Platelets were labeled with carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE) and adjusted to a final concentration of 200   106
platelets/250  l as described previously (59).
FeCl3-induced arterial thrombosis model. 4–5-wk-old mice were
anesthetized by i.p. injection of 2,2,2-tribromoethanol and 2-methyl-
2-butanol (0.15 ml/10 g of body weight from a 2.5% solution; Sigma-
Aldrich). 108 CFSE-labeled platelets per mouse were injected through the tail
vein. The mesentery was externalized through a midline abdominal incision.
35–60- m-diameter arterioles were visualized at 10  with an inverted mi-
croscope (Axiovert 200; Carl Zeiss MicroImaging, Inc.) equipped with a 100-W
fluorescent lamp source (HBO) and a CCD camera (CV-M300; Visitron Sys-
tems GmbH) connected to an S-VHS video recorder (AG-7355; Panasonic). Af-
ter topical application of a filter paper (2   1 mm) saturated with 20% FeCl3
for 1 min, arterioles were monitored for 40 min or until complete occlusion
(blood flow stopped for  1 min) occurred as described previously (60). Plate-
let adhesion was defined as the number of fluorescently labeled platelets
bound to the vessel wall 5 min after injury. A thrombus was defined as a
platelet aggregate  20  m in diameter. In some experiments, human FXII
(American Diagnostica, Inc.) was injected i.v. directly before the experiment.
Intravital microscopy of thrombus formation in the carotid ar-
tery. Intravital microscopy of injured carotid arteries was performed as pre-
viously described (19). In brief, mice were anesthetized by i.p. injection of
ketamine/xylazine (100:5 mg/kg; Parke-Davis and Bayer AG, respectively).
Polyethylene catheters (Portex) were implanted into the right jugular vein,
and 2   108 fluorescent platelets/250  l were infused i.v. Carotid injury
was induced by ligation with a surgical filament. Before and after vascular
injury, fluorescent platelets were visualized in vivo by video microscopy of
the right common carotid artery using a microscope (Axiotech; Carl Zeiss
MicroImaging, Inc.) with a 20  water immersion objective and a 100-W
mercury lamp (HBO) for epiillumination. Platelet adhesion and thrombus
formation were observed for 5 min after injury, and videotaped images
were evaluated using a computer-assisted image analysis program (Visitron)
as previously described (61).
Collagen/epinephrine-induced pulmonary thromboembolism.
Mice were anesthetized by i.p. injection of 2,2,2-tribromoethanol and
2-methyl-2-butanol (0.15 ml/10 g of body weight from a 2.5% solution),
and a mixture of 0.8 mg/kg of collagen and 60  g/kg of epinephrine was
injected into the jugular vein (62). Platelet counts were determined by flow
cytometry on a FACSCalibur (Becton Dickinson). Results are expressed as
mean   SD or as percentage of control.
Histopathologic analyses. Mice were killed, and lungs were rapidly re-
moved and fixed at 4 C for 24 h in buffered 4% formalin, pH 7.4. Tissues were
dehydrated and embedded in paraffin (Histolab Products AB), cut into 4- m
sections, and stained with Mayer’s hematoxylin and eosin (Sigma-Aldrich).
Aorta occlusion model. The abdominal cavities of anesthetized mice
were opened with longitudinal incisions, and an ultrasonic flow probe
(Transonice Systems, Inc.) was placed around the abdominal aortas. Throm-
bus formation was induced by a single firm compression of the vessel with
forceps immediately downstream from the flow probe. Blood flow was
monitored until complete occlusion occurred or for 40 min.
Preparation of antimurine FXII antibody. Murine FXII heavy chain
was expressed as a GST fusion protein in Escherichia coli BL21, and poly-
clonal anti-FXII antibodies were raised in rabbits according to standard im-
munization protocols.
SDS-PAGE and Western blotting. 0.3  l plasma/lane was separated by
12.5% SDS-PAGE, transferred onto nitrocellulose membranes, and probed
with the anti–high molecular mass kininogen antibody MBK3 (donated by
W. Müller-Esterl, University of Frankfurt, Frankfurt, Germany), the anti–
plasma kallikrein antibody AS176 (63), and anti–murine FXII antibodies in
1:1,000 dilutions, respectively. Bound antibodies were detected using per-
oxidase-conjugated secondary antibodies followed by a chemiluminescence
detection method.
Measurement of thrombin generation. Thrombin generation was
measured according to the method of Aronson with minor modifications as
previously described (64) using the chomogenic substrate S-2238 (H–D–
Phe–Arg–NH–NO2–HCl; Chromogenix). The absorbance of the released
product was measured spectrophotometrically at 405 nm. Measurements
were obtained in triplicate at each time point.
Coagulation assays. Washed platelets from WT or FXII /  mice were
resuspended in Tyrode buffer supplemented with 4 mM Ca2  and 5  M
Ca2  ionophore A23187 (Sigma-Aldrich) for 10 min before suspension in
PFP. Clot formation was initiated by recalcification with 100  l/25 mM
CaCl2 solution in a “Kugelkoagulometer” (KC10; Amelung) at 37 C, and
the time to clot formation was recorded using a coagulation timer (KC4;
Amelung). For the determination of the recalcification clotting time, 100  l
of citrate anticoagulated mouse plasma (0.38% sodium citrate), was incubated
with 100  g each of Horm type collagen (Nycomed), kaolin (final concen-
trations, 30  g/ml), or buffer for 120 s at 37 C before addition of CaCl2.
Coagulation analysis. Global coagulation parameters were determined
with an automated blood coagulation system (BCS; Dade Behring) with re-
agents according to the protocols for human samples detailed by the manu-
facturer (http://www.dadebehring.com). Peripheral blood counts were de-
termined on the Sysmex XE 2100 (Diamond Diagnostics) according to
standard protocols.
Statistical evaluation. Statistical analysis was performed using the un-
paired Student’s t test.
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